Schering hit by currency woes and lower prices:
This article was originally published in Clinica
Executive Summary
Increased sales in volume terms at German company Schering's diagnostics division were not enough to compensate for lower prices and currency effects in the first half of 1998. Diagnostic sales fell 4% to DM737 million ($416 million), with sales of X-ray contrast media fell 1% to DM549 million. Sales of MRI products fell 13% to DM184 million, largely due to stock reductions by US partner, Abbott Laboratories. The Berlin-based company's total sales increased 4% to DM3,216 million, while net income rose 8% to DM307 million.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.